1. Home
  2. NVCR

NVCR

NovoCure Limited

Logo NovoCure Limited

Health Care

Medical/Dental Instruments

Nasdaq

as 04-19-2024 12:17pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

Founded: 2000 Country:
Jersey
Jersey
Employees: N/A City: ST. HELIER
Market Cap: 1.5B IPO Year: 2015
Target Price: $45.89 AVG Volume (30 days): 1.3M
Analyst Decision: Buy Number of Analysts: 9
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.95 EPS Growth: N/A
52 Week Low/High: $10.87 - $83.60 Next Earning Date: 05-02-2024
Revenue: $509,338,000 Revenue Growth: -5.30%
Revenue Growth (this year): 7.8% Revenue Growth (next year): 7.87%

Share on Social Networks: